In addition, levels of MMP-9 were reduced after treatment of linagliptin, an inhibitor for dipeptidyl peptidase-4 enzyme to attenuate aberrant biosynthesis and secretion of insulin to treat Type 2 diabetes (Fig 8A). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.